Should I buy Haemonetics (HAE) stock or is it too late?

Haemonetics · Health Care · price $122

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Citigroup — 65% of its targets hit on this sector (128 calls tested). It aims for $123 (+1.1 %), call made on September 18, 2026, maturing on September 18, 2027 (26 d ago).

The 5 reliable analysts $123+1.1 %

The 3 other firms $125+2.7 %

How to read it: the 5 reliable firms are not filtered by optimism — 3 aim above the price, 2 below, hence their $123 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Haemonetics

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Mizuho	60 %	+12.4 %	5	$140 +15%
JMP Securities	55 %	+10.8 %	11	$100 -18%
Jefferies	60 %	+4.2 %	10	$85 -30%
Barrington Research	44 %	+3.5 %	25	$140 +15%
Raymond James	42 %	-6.0 %	24	$125 +3%
Needham	27 %	-10.9 %	11	$78 -36%
Morgan Stanley	56 %	-6.0 %	9	—

In short — Should you invest in Haemonetics? Is it too late, still worth it? Analysts are overwhelmingly positive (88% buy, median target $124, i.e. +2%), and the most reliable on HAE targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

88% of analysts rate it a buy (Buy consensus, 8 ratings) — a sign of market conviction.
The most reliable firm on HAE, Mizuho (60% hit rate, 5 scored calls), targets $140 (call made on October 9, 2026, maturing on October 9, 2027) (+15%) in its most recent call, and $90 (call made on December 17, 2025, maturing on December 17, 2026) (-26%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 8 ratings, 1 is neutral.
Limited upside: the median target is only +2% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on HAE

Median target $124 (+2%) · 8 ratings · Buy consensus

Strong Buy00%

Buy788%

Hold113%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Haemonetics now?

We won't decide for you. The facts: 88% of analysts rate it a buy, median target $124 (+2%), and Mizuho (most reliable on HAE, 60%) targets $140. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Haemonetics?

The stated upside is small: the median target ($124) sits just +2% from the price ($122) (most reliable on HAE: Mizuho, 60%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Haemonetics still worth investing in?

It depends on the gap between the price ($122) and its estimated value: analysts target $124 on median (+2%), with 88% buys (most reliable on HAE: Mizuho, 60%). Cross-check with their real reliability on HAE and the cautions above. Information, not advice.

What's the main risk in buying HAE?

The consensus is not unanimous: of 8 ratings, 1 is neutral.

→ Go deeper: the full Haemonetics profile (consensus, analyst reliability, price target, performance).